WO1994026787A1 - Procede pour generer des bibliotheques d'anticorps de phages specifiques de types cellulaires - Google Patents
Procede pour generer des bibliotheques d'anticorps de phages specifiques de types cellulaires Download PDFInfo
- Publication number
- WO1994026787A1 WO1994026787A1 PCT/US1994/005124 US9405124W WO9426787A1 WO 1994026787 A1 WO1994026787 A1 WO 1994026787A1 US 9405124 W US9405124 W US 9405124W WO 9426787 A1 WO9426787 A1 WO 9426787A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- target cells
- cell
- phage particles
- phage
- target
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 48
- 239000002245 particle Substances 0.000 claims abstract description 47
- 239000000427 antigen Substances 0.000 claims abstract description 42
- 108091007433 antigens Proteins 0.000 claims abstract description 42
- 102000036639 antigens Human genes 0.000 claims abstract description 42
- 241000724791 Filamentous phage Species 0.000 claims abstract description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 230000020411 cell activation Effects 0.000 claims description 3
- 230000022534 cell killing Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 238000001042 affinity chromatography Methods 0.000 claims description 2
- 239000011324 bead Substances 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 230000003834 intracellular effect Effects 0.000 claims description 2
- 238000004091 panning Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 238000003364 immunohistochemistry Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 136
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 6
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 5
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 5
- 238000003314 affinity selection Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 4
- 102000013925 CD34 antigen Human genes 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 108050003733 CD34 antigen Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 description 1
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 description 1
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 description 1
- -1 IL2R p55 chain Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 108010003510 anhydrotrypsin Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
Definitions
- the invention relates generally to the field of cell type specific phage antibody libraries, and relates specifically to the field of generating such libraries by direct affinity selection on the surface of target cells.
- the phage antibody technology is a recently developed technique that allows the expression of monoclonal antibodies on the surface of filamentous phage particles (see, for example, Smith, Science 228, 1315-1317 (1985); Barbas et al., Proc. Natl. Acad. Sci. USA 88, 7978-7982 (1991); Clackson et al., Nature 352, 624-628 (1991)).
- One advantage of this technology is the linkage of the specificity of a monoclonal antibody with the genetic information encoding the specificity in the same phage particle, thus allowing enrichment of specific phage antibodies by binding to purified antigens attached to a solid phase, followed by elution and amplification of the phage particles.
- Such a method is described in Kang et al., Proc.Natl.Acad.Sci.USA 88, 4363-4366 (1991).
- micropanning or affinity column techniques researchers have used this technology to generate antibodies reactive to well-characterized antigens that can be purified in large quantities, either as natural or recombinant products, including various hapterts, tetanus toxoid, HTV and RSV glycoproteins, HBV core and surface antigens, progesterone, thyroglobulin, TNF alpha, CEA, soluble CD4, IL2R p55 chain, lysozyme, bovine serum albumin, trypsin, anhydrotrypsin, and L6 tumor-associated antigen.
- natural or recombinant products including various hapterts, tetanus toxoid, HTV and RSV glycoproteins, HBV core and surface antigens, progesterone, thyroglobulin, TNF alpha, CEA, soluble CD4, IL2R p55 chain, lysozyme, bovine serum albumin, trypsin, anhydro
- the present invention involves methods for using the phage antibody technology to generate antibodies directed against previously unknown and unpurified antigens on the cell surface, e.g., as a way to discover new antigens on important cell types. Since a phage antibody may be amplified by growing the phage in bacteria, it is possible to recover a single phage particle specifically bound to an antigen in order to generate enough monoclonal antibodies for detailed characterization of the antigen. The high sensitivity of the method enables isolation of antibodies directed against an unpurified antigen in the midst of numerous background antigens.
- target antigens on the surface of a phenotypically defined population of cells are used to separate phage antibodies reactive to the antigens from the background.
- the cell membrane of the target cells can be considered a solid phase support for a set of cell type specific antigens, and the intact target cells can be used as a convenient physical device to separate phage antibodies bound on the surface of the target cells from the unbound phage antibodies.
- the inventive method for generating antibodies against previously uncharacterized and unpurified antigens on the surface of target cells in a cell population includes incubating a combinatorial library of antibodies expressed on the surface of filamentous phage particles with a target cell population under conditions sufficient to bind a portion of the phage particles to the target cells.
- the target cells and bound phage particles are then separated from the unbound phage particles, and the bound phage particles are recovered.
- These phage particles are then amplified to create an enriched library.
- Monoclonal antibodies specific to the target cell are then isolated from the enriched library for subsequent use.
- the phage antibody library may be preadsorbed with an excess of non-target cells to immunologically remove antibodies directed against antigens present on non-target cells.
- the adsorption step may be performed after the phage antibody selection and amplification, or prior to the initial incubating step.
- the removal of these antibodies can be done by subtraction hybridization of DNA from a phage antibody library enriched with the target cells to DNA from a library enriched with non-target cells.
- the phenotypically defined target cell population may be isolated prior to incubating the target cells with the phage antibody library, or the target cells may be a subpopulation within a heterogeneous cell population and be isolated after incubating with the phage antibody library, thus copurifying the phage antibodies bound to the cell surface antigens.
- FIGURE 1 is a flow chart illustrating an embodiment of the present inventive method.
- FIGURE 2 is a flow chart illustrating another embodiment of the present inventive method.
- FIGURES 3a - 3d are histograms showing indirect immunofluorescence patterns of KGla cells and mouse thymocytes stained with the unenriched and enriched antibody libraries.
- the abscissa indicates relative fluorescence intensity, and the ordinate indicates relative cell number.
- the process of the present invention includes a method to generate antibodies against cell surface antigens by direct affinity selection of phage antibodies on the surface of target cells.
- a phage antibody library is constructed by standard methods and an aliquot of the library is used for incubation with the target cells.
- Phage antibodies that are specific to and have a high affinity for antigens on the target cells will tightly bind to the cells and can be separated from the rest of the phage antibody library by washing and spinning down the cells.
- the bound phage particles can then be eluted from the cell surface, recovered, and amplified to yield an enriched phage antibody library.
- the present method involves a first step of incubating (100) a standard phage antibody library, such as a combinatorial library of antibodies expressed on the surface of filamentous phage particles, with a target cell population.
- a standard phage antibody library such as a combinatorial library of antibodies expressed on the surface of filamentous phage particles
- the cells are incubated under conditions sufficient to bind a portion of the phage particles to the target cells.
- the target cell population is an isolated cell population.
- the process of the present invention preferably utilizes a standard combinatorial phage antibody library of 10 ⁇ recombinants, which may be prepared using standard protocols, such as that described in Barbas et al., Methods 2, 119-124 (1991).
- the cell population may be isolated according to any preselected criteria.
- the target cells and the phage particles bound thereto are separated (102) from the unbound phage particles.
- Phage antibodies that are specific to and have a high affinity for antigens on the target cells will tightly bind to the cells and can be separated from the rest of the phage antibody library by centrifugating the cells through a calf serum cushion.
- Other standard separation methods known by those skilled in the relevant art may be used, examples including but not limited to, cell washing and centrifugation, filtration of the unbound phages through a membrane, and immobilization or capture of the cells on a solid phase.
- the separated phage particles, or phage antibodies, are then recovered (104).
- the bound phage particles may be eluted, for example using an acidic buffer, from the cell surface using standard methods.
- the resulting recovered phage antibodies are amplified (106) to yield an enriched phage antibody library. Repeating this enrichment step several times generates a phage antibody library with high specificity for surface antigens on the target cells. Each round of enrichment increases the representation of antibodies with higher affinity for the target antigens but decreases the diversity of the library. Thus, the amount of enrichment will depend on the particular requirements of the user.
- monoclonal antibodies specific for the target cells are isolated (108) from the library.
- phage antibodies reactive to antigens on the target cell population are obtained.
- the monoclonal antibodies are isolated (108) using methods known and available to those skilled in the art.
- direct affinity selection of the phage antibodies on the cell surface is used as described substantially above.
- a population of isolated target cells are incubated with the phage antibody library.
- the target cells may be in the form of a cell line, or other substantially isolated population of target cells.
- the target cell population is a subpopulation from a heterogeneous cell population before any isolation.
- the target cell population may subsequently be separated (110) from other cells in the heterogeneous population based on phenotypic distinctions, or other appropriate distinctions, thus copurifying the phage particles bound to the cell surface (112).
- the target cells are phenotypically defined target cell subpopulations.
- This allows generation of antibodies against rare but phenotypically defined cell subpopulations that are too few in cell number to allow characterization by conventional methods.
- the phage antibody library is first allowed to bind to the total and unpurified cell population.
- the target subpopulation is then physically separated from the rest of the cells by means of its defining phenotypic characteristics.
- the phage particles specifically bound to the surface antigens of the target cells are separated (112) out together with the target cell subpopulation.
- phage antibodies reactive to antigens on the target subpopulation of a heterogeneous population may be selectively enriched by copurification of the target cells with their specific phage antibodies, exploiting the phenotypic characteristics of the target cells. Standard methods of cell separation known to those skilled in the art may be used.
- the method to be used for the copurification (112) step may be any of the type known and available to those skilled in the art.
- Exemplary methods applicable to target cells in suspension include fluorescence-activated cell sorting (FACS), immunological panning, magnetic bead separation, and affinity chromatography.
- FACS fluorescence-activated cell sorting
- the specific copurification method will depend on availability of materials, the type of target cell subpopulation, and other factors determinable by those skilled in the art.
- the cell population used in conjunction with the present method may include whole tissue sections, such as frozen tissue sections, in which the target cell population is identifiable. Exemplary methods for identifying and isolating target cell subpopulations may include use of immunohistochemical markers, physical location of cell populations, or other methods known and used by those skilled in the art.
- tissue sections the tissue section is incubated with the phage antibody library under conditions sufficient to bind phage particles to the target cells. The target cells and the bound phage particles are then microdissected from the tissue section, the phage particles are recovered and amplified, and monoclonal antibodies are isolated in accordance with the method described above.
- the preferred embodiment of the invention makes use of the phenotypic characteristics of the target cells to identify phage antibodies of interest by means of their binding to the target cells.
- phage antibodies are selected if they are shown to have an identifiable and preselected function, as compared with other phage antibodies without such function.
- phage antibodies may be assayed, for example, for the functional consequences of a phage antibody-target cell binding.
- One assay may be to measure intracellular calcium concentration.
- Another effective assay may be used to detect cell activation, cell proliferation, or cell killing, or the blocking of these activities.
- Yet another assay may be to analyze the expression of preselected genes.
- Other functional methods of identifying phage antibodies known and available to those skilled in the art may be used.
- the resulting phage antibody library may contain antibodies reactive to antigens unique to the target cells and antibodies reactive to antigens present on both the target cells and non-target cells. It may be desirable to selectively remove the antibodies reactive to antigens not unique to the target cells. This may be accomplished by preadsorbing the phage antibody library with an excess of non-target cells to immunologically remove phage antibodies directed against antigens present on non-target cells. This additional step may be performed either prior to incubating the phage antibody library with the cell population, or prior to isolating monoclonal antibodies from the enriched library.
- the goal of selectively enriching phage antibodies directed against antigens present only on target cells and not on non-target cells can also be achieved by DNA subtraction hybridization.
- two cell type specific phage antibody libraries are generated using the present inventive method, one for the target cells and one for the non-target cells.
- DNA encoding antibodies directed against antigens present on both cell types are then removed from the first library by hybridizing DNA from the first library to an excess of DNA from the second library and subsequently removing the annealed hybrids.
- the resulting subtracted phage antibody library will then contain mostly antibodies directed against antigens unique to the target cells. Standard methods of DNA subtraction hybridization known to those skilled in the relevant art, or variations of these methods, may be used in this step.
- KGla cell line is an available human myeloblastoid cell line, and is characterized in several publications, including Koeffler et al., Blood 56, 265-273 (1980).
- spleen cells are isolated from the animals, lymphocytes are separated on a Ficoll-PaqueTM gradient, commercially available from Pharmacia LKB Biotechnology, Inc., Piscataway, New Jersey, and total RNA is prepared using standard, known techniques.
- a combinatorial phage antibody library of 10 ⁇ recombinants is prepared using standard protocols as described in Barbas et al., Methods 2, 119-124 (1991), and as described in further detail below.
- KGla cells are incubated with phage particles from the combinatorial library in binding buffer on ice for 30 minutes, and then spun through a calf serum cushion three times. Phage particles bound to the surface of the cells are eluted in an acid buffer (such as 0.1 M HC1, adjusted with glycine to pH 2.2; and BSA lmg/ml), recovered, and used to infect XLl-Blue bacteria, available from Stratagene Cloning Systems, La Jolla, California. The phagemids in the infected bacteria are expanded in culture and rescued with helper phage VCSM13 to yield an enriched phage antibody library. The library is then used in another round of enrichment.
- an acid buffer such as 0.1 M HC1, adjusted with glycine to pH 2.2; and BSA lmg/ml
- Table 1 lists the number of phage particles recovered after each round of enrichment, showing a steady increase in the number of recovered phage particles after each round.
- a negative control experiment (results not shown) using mouse thymocytes as the target cells for binding with the phage shows no increase in the number of phage particles recovered.
- FIGURES 3(a) through 3(d) are histograms showing fluorescence patterns of KGla cells and mouse thymocytes stained with the unenriched (a,c) or enriched (b,d) antibody libraries. The abscissa indicates relative fluorescence intensity and the ordinate indicates relative cell number.
- Fab fragments are produced separately from ten individual clones picked at random from the library. FACS analysis of these samples (results not given) shows that the Fab fragments from all of the ten clones strongly react with KGla cells and with variable patterns, indicating that all of the ten monoclonal antibodies are specific for KGla and probably recognize at least several different surface antigens on the cells.
- the entire enriched antibody library most likely contains a large number of monoclonal antibodies recognizing many different surface antigens on KGla cells.
- KGla cells which bear the human CD34 antigen on their surface, are stained with CD34-specific antibodies according to Civin et al., T.Immunol 133, 157-165 (1984), and spiked at a ratio of 1 to 10 or 1 to 100 into mouse thymocytes, which are CD34 antigen negative.
- the cell mixtures are incubated with an unenriched phage antibody library and sorted for CD34 antigen positive (CD34+) cells by FACS. Phage particles bound on the surface of the sorted cells are recovered by acid elution and used to infect XLl-Blue bacteria.
- An enriched phage antibody library is then produce by helper phage rescue of the phagemids in the infected bacteria and used in another round of enrichment.
- Table 2 the number of phage particles recovered from the sorted CD34+ cells increases dramatically after three rounds of selection, suggesting effective enrichment of specific phage antibody by the copurification method described in detail above.
- Fab fragments are produced from the enriched library and used for staining KGla and mouse thymocytes. FACS analysis using these Fab fragments show a strong reaction with the KGla cells but no reaction with the mouse thymocytes (results not shown). Fab fragments from the unenriched library give signals similar to the background. This result demonstrates the feasibility of producing specific monoclonal antibodies directed against a rare population of cells using the combined strategies of cell surface selection and target cell copurification.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne un procédé pour générer des anticorps monoclonaux dirigés contre des antigènes non caractérisés précédemment et non purifiés, sur la surface de cellules cibles dans une population de cellules. Le procédé consiste à incuber (100) une bibliothèque combinatoire d'anticorps exprimés sur la surface de particules filamenteuses de phages avec une population de cellules cibles dans des conditions permettant de fixer une portion des particules de phages aux cellules cibles. Les cellules cibles et les particules de phages sont alors séparées (102) des particules de phages non liées et les particules de phages liées sont récupérées (104). Ces particules de phages sont alors amplifiées (106) pour créér une bibliothèque enrichie. Les anticorps monoclonaux spécifiques des cellules cibles sont alors isolés (108) de la bibliothèque enrichie, pour une utilisation ultérieure.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5932393A | 1993-05-07 | 1993-05-07 | |
US08/059,323 | 1993-05-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994026787A1 true WO1994026787A1 (fr) | 1994-11-24 |
Family
ID=22022244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/005124 WO1994026787A1 (fr) | 1993-05-07 | 1994-05-04 | Procede pour generer des bibliotheques d'anticorps de phages specifiques de types cellulaires |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1994026787A1 (fr) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997022972A3 (fr) * | 1995-12-15 | 1997-08-21 | Upjohn Co | Procede pour la detection simultanee d'une cible therapeutique pour un etat pathologique et de sa molecule de type anticorps neutralisant |
US5721342A (en) * | 1989-11-13 | 1998-02-24 | British Technology Group Limited | Control of milk secretion |
WO1998034110A1 (fr) * | 1997-01-31 | 1998-08-06 | Active Biotech Ab | Identification in situ de structures cibles p.ex. procede de selection in vivo destine a une banque de bacteriophages |
WO1998039469A1 (fr) * | 1997-03-04 | 1998-09-11 | Bio-Technology General Corp. | Isolement de ligands peptidiques a specificite tissulaire et utilisation de ces derniers pour cibler des substances pharmaceutiques sur des organes |
WO1998049286A3 (fr) * | 1997-05-01 | 1999-03-25 | Univ Texas | Evolution orientee d'enzymes et d'anticorps |
WO1999056129A1 (fr) * | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | Procedes de selection d'anticorps d'internalisation |
WO1999041402A3 (fr) * | 1998-02-11 | 1999-11-11 | Maxygen Inc | Ciblage de vecteurs de vaccins genetiques |
WO2000014215A1 (fr) * | 1998-09-07 | 2000-03-16 | Eberhard-Karls-Universität Tübingen | Procede de selection de peptides pour le transport cible de medicaments et de marqueurs et peptides decouverts a l'aide dudit procede |
US6057098A (en) * | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
US6190856B1 (en) * | 1996-05-22 | 2001-02-20 | The Johns Hopkins University | Methods of detection utilizing modified bacteriophage |
WO2001025492A1 (fr) * | 1999-10-02 | 2001-04-12 | Biosite Diagnostics Inc. | Anticorps humains |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
US6277583B1 (en) * | 1996-02-07 | 2001-08-21 | Conjuchem, Inc. | Affinity labeling libraries and applications thereof |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
US6924359B1 (en) | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
US7132510B2 (en) | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
US7288249B2 (en) | 1999-03-01 | 2007-10-30 | Genentech, Inc. | Antibodies for cancer therapy and diagnosis |
US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0460607A2 (fr) * | 1990-06-05 | 1991-12-11 | Bristol-Myers Squibb Company | Nouvel anticorps monoclonal contre un antigène nouveau associé aux tumeurs humaines |
-
1994
- 1994-05-04 WO PCT/US1994/005124 patent/WO1994026787A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0460607A2 (fr) * | 1990-06-05 | 1991-12-11 | Bristol-Myers Squibb Company | Nouvel anticorps monoclonal contre un antigène nouveau associé aux tumeurs humaines |
Non-Patent Citations (3)
Title |
---|
HARLOW et al., "Antibodies a Laboratory Manual", Published 1988, by COLD SPRING HARBOR LABORATORY (N.Y.), pages 496-497. * |
J. IMMUNOLOGY, Vol. 135, No. 4, issued October 1985, LEDBETTER et al., "Antibodies to TP67 and TP44 Augment and Sustain Prolifferative Response of Activated T Cells", pages 2331-2336. * |
NATURE, Vol. 308, issued 08 March 1984, HENDRICK et al., "Isolation of CDNA Clones Encoding T Cell-Specific Membrane-Associated Proteins", pages 149-153. * |
Cited By (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5721342A (en) * | 1989-11-13 | 1998-02-24 | British Technology Group Limited | Control of milk secretion |
US6858384B2 (en) * | 1995-06-07 | 2005-02-22 | Crucell Holland B.V. | Phage antibodies |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
WO1997022972A3 (fr) * | 1995-12-15 | 1997-08-21 | Upjohn Co | Procede pour la detection simultanee d'une cible therapeutique pour un etat pathologique et de sa molecule de type anticorps neutralisant |
US6277583B1 (en) * | 1996-02-07 | 2001-08-21 | Conjuchem, Inc. | Affinity labeling libraries and applications thereof |
US6190856B1 (en) * | 1996-05-22 | 2001-02-20 | The Johns Hopkins University | Methods of detection utilizing modified bacteriophage |
WO1998034110A1 (fr) * | 1997-01-31 | 1998-08-06 | Active Biotech Ab | Identification in situ de structures cibles p.ex. procede de selection in vivo destine a une banque de bacteriophages |
US6727062B1 (en) | 1997-01-31 | 2004-04-27 | Active Biotech Ab | Identification of target structures E.G. in vivo selection method for a phage library |
WO1998039469A1 (fr) * | 1997-03-04 | 1998-09-11 | Bio-Technology General Corp. | Isolement de ligands peptidiques a specificite tissulaire et utilisation de ces derniers pour cibler des substances pharmaceutiques sur des organes |
US6057098A (en) * | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
US6986986B1 (en) | 1997-04-04 | 2006-01-17 | Joe Buechler | Polyvalent display libraries |
WO1998049286A3 (fr) * | 1997-05-01 | 1999-03-25 | Univ Texas | Evolution orientee d'enzymes et d'anticorps |
US7390619B1 (en) | 1998-02-11 | 2008-06-24 | Maxygen, Inc. | Optimization of immunomodulatory properties of genetic vaccines |
WO1999041402A3 (fr) * | 1998-02-11 | 1999-11-11 | Maxygen Inc | Ciblage de vecteurs de vaccins genetiques |
WO1999056129A1 (fr) * | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | Procedes de selection d'anticorps d'internalisation |
US8974792B2 (en) | 1998-04-24 | 2015-03-10 | The Regents Of The University Of California | Internalizing erbB2 antibodies |
US9388244B2 (en) | 1998-04-24 | 2016-07-12 | The Regents Of The University Of California | Internalizing ErbB2 antibodies |
US8173424B2 (en) | 1998-04-24 | 2012-05-08 | The Regents Of The University Of California | Internalizing ErbB2 antibodies |
US7892554B2 (en) | 1998-04-24 | 2011-02-22 | The Regents Of The University Of California | Internalizing ErbB2 antibodies |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
WO2000014215A1 (fr) * | 1998-09-07 | 2000-03-16 | Eberhard-Karls-Universität Tübingen | Procede de selection de peptides pour le transport cible de medicaments et de marqueurs et peptides decouverts a l'aide dudit procede |
US7288249B2 (en) | 1999-03-01 | 2007-10-30 | Genentech, Inc. | Antibodies for cancer therapy and diagnosis |
US7858092B2 (en) | 1999-07-01 | 2010-12-28 | Yale University | Neovascular-targeted immunoconjugates |
US6924359B1 (en) | 1999-07-01 | 2005-08-02 | Yale University | Neovascular-targeted immunoconjugates |
US8388974B2 (en) | 1999-07-01 | 2013-03-05 | Yale University | Neovascular-targeted immunoconjugates |
US8071104B2 (en) | 1999-07-01 | 2011-12-06 | Yale University | Neovascular-targeted immunoconjugates |
US6794132B2 (en) | 1999-10-02 | 2004-09-21 | Biosite, Inc. | Human antibodies |
US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
WO2001025492A1 (fr) * | 1999-10-02 | 2001-04-12 | Biosite Diagnostics Inc. | Anticorps humains |
US7189515B2 (en) | 1999-12-06 | 2007-03-13 | Biosite, Inc. | Human antibodies as detection reagents |
US6680209B1 (en) | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
US7132510B2 (en) | 2000-12-29 | 2006-11-07 | Bio-Technology General (Israel) Ltd. | Specific human antibodies for selective cancer therapy |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1994026787A1 (fr) | Procede pour generer des bibliotheques d'anticorps de phages specifiques de types cellulaires | |
US5646001A (en) | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof | |
JP3135126B2 (ja) | 疾患の臨床的発現に基づく、診断用試薬を得る方法、アッセイ、及び治療剤 | |
CN100494399C (zh) | 一种基于dna芯片的基因分型方法及其应用 | |
US5378624A (en) | Methods for removing ligands from a particle surface | |
AU699568B2 (en) | A method for identification of biologically active peptides and nucleic acids | |
JP2004173681A (ja) | 抗原特異的リンパ球検出用マイクロウェルアレイチップ、抗原特異的リンパ球の検出法及び製造方法 | |
JPH03277972A (ja) | リステリア菌の検出方法 | |
JP3901222B2 (ja) | 細胞への抗体結合の検出のための組成物および方法 | |
Sekine et al. | Panning of multiple subsets of leukocytes on antibody-decorated poly (ethylene) glycol-coated glass slides | |
Kumar et al. | Cell Separation: Fundamentals, Analytical and Preparative Methods | |
WO1998016541A9 (fr) | Triage de cellules activees magnetiquement permettant la production de proteines | |
Cullis et al. | Isolation of tissue culture-induced polymorphisms in bananas by representational difference analysis | |
AU1477299A (en) | Selective technique for rapid identification of proteins and genes and uses thereof | |
US20250003958A1 (en) | Reagent for preparing a cell sample | |
JP6959138B2 (ja) | 免疫レパートリーの疾患関連cdr3パターンを同定するための方法 | |
Terzaghi et al. | The role of the collar/whisker complex in bacteriophage T4D tail fiber attachment | |
CN113699157A (zh) | Pd-l1核酸适配体、其筛选方法及应用 | |
JP4729043B2 (ja) | 抗体ライブラリーをスクリーニングする方法 | |
EP4606895A1 (fr) | Procédé de construction de banque multi-comique, procédé de détection et kit connexe | |
Hammond et al. | Subdivision of HL‐A5 and comparative studies of the HL‐A polymorphism in South African Indians | |
CN120366199A (zh) | 一种脑组织血管壁细胞的提取方法 | |
AU2339199A (en) | Methods for identifying therapeutic targets | |
EP4445135A1 (fr) | Isolement et diagnostic de cellules foetales | |
EP0535376A1 (fr) | Procédé analytique pour un polymère |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |